Cervical Cancer Deaths Fall to Zero in Young English Women Following HPV Vaccine Rollout

For the first time in recorded medical history, a demographic of young women in England has experienced exactly zero deaths from cervical cancer over a five-year period. Between 2020 and 2024, not a single woman aged 20 to 24 died from the disease, marking a monumental victory for public health and modern medicine.[1][2]

The milestone is the direct result of the UK’s human papillomavirus (HPV) vaccination program, which was first rolled out to 12- and 13-year-old girls in 2008. The young women in the 20-24 age bracket today represent the first cohort to have been offered the jab routinely in early adolescence, providing the first definitive look at the vaccine's long-term impact on mortality.[1][3]

According to a groundbreaking study published in The Lancet and spearheaded by Queen Mary University of London, the vaccine has effectively eliminated cervical cancer mortality for this age group. Researchers estimate that without the vaccine, around 23 deaths would have been expected in this specific demographic during that four-year window.[2][4]

The mechanism behind this success lies in severing the link between a common virus and cellular mutation. Cervical cancer is the fourth most common cancer in women globally, and high-risk strains of HPV are responsible for 99% of all cases.[2]

HPV is a highly transmissible virus passed through close skin-to-skin contact. While most infections clear up naturally without the host ever knowing they were infected, certain high-risk strains can linger in the body for years. Over time, these persistent infections cause abnormal changes to cervical cells, which can slowly develop into cancer.[4][6]

The HPV vaccine works by triggering the immune system to produce antibodies against these specific high-risk strains before a person is ever exposed to them. Because the vaccine is administered in early adolescence—ideally before any sexual contact occurs—it effectively builds an impenetrable shield against the virus, stopping the cascade of cellular damage before it can begin.[3][4]

The broader data from the Queen Mary University study reveals a cascading effect of lives saved. Across all age groups studied, the vaccine has prevented an estimated 200 young women from dying of cervical cancer in England since the program's inception.[3][5]

The protective benefits extend well into adulthood. For vaccinated women who are now aged 30 to 34, the relative risk of death from cervical cancer is 63% lower compared to unvaccinated cohorts. For those inoculated at age 12 or 13, the likelihood of dying from the disease before their 30th birthday is now considered to be almost zero.[2][3]

Professor Peter Sasieni, the study’s lead author, described the current data as merely the "tip of the iceberg." As the generations of girls who received the vaccine in the late 2000s and 2010s continue to age into their 40s and 50s—traditionally the decades when cervical cancer incidence peaks—epidemiologists expect to see thousands of additional lives saved.[3][5]

The UK has also expanded its defensive perimeter. In 2019, the National Health Service began offering the HPV vaccine to boys as well. This dual-gender approach not only protects men from HPV-related head, neck, and penile cancers, but it also drastically reduces the overall circulation of the virus, creating robust herd immunity that protects those who cannot be vaccinated.[5][6]

However, public health authorities are warning that this hard-won progress is currently under threat. Despite the vaccine's proven near-100% efficacy in preventing mortality in the youngest cohort, uptake rates have slipped alarmingly in the wake of the COVID-19 pandemic.[2][4]

The World Health Organization has set a global target for countries to vaccinate 90% of girls by the age of 15. While England was close to this target prior to 2020, recent data shows that only 71.7% of girls and 67% of boys in Year 8 received the vaccine during the 2024-2025 school year. In London, the rate for girls plummeted to just 62.6%.[3][6]

Cancer Research UK, which funded the Lancet study, notes that this drop means roughly one in four young people are currently leaving school unprotected. The decline is attributed to a combination of pandemic-era disruptions to school-based health programs and a broader, generalized rise in vaccine hesitancy.[3][4]

Experts caution that if these vaccination rates do not return to pre-pandemic levels, the UK could see a tragic reversal of the current trend, with an estimated 15 to 25 avoidable deaths occurring each year in young women.[2]

Furthermore, medical professionals stress that the vaccine does not eliminate the need for routine cervical screening, commonly known as a smear test. Because the vaccine protects against the most dangerous strains of HPV but not every single variant, regular screenings remain a vital second line of defense to catch any abnormal cells early.[3][4]

Ultimately, the data out of England provides the strongest proof of concept yet that cervical cancer is a preventable disease. With sustained investment in school vaccination programs and continued public participation in screening, a future where the disease is entirely eradicated is now firmly within scientific reach.[4][5]